Zyus Life Sciences Corporation (TSE:ZYUS) has released an update.
ZYUS Life Sciences Corporation has successfully completed its annual financial filings after a delay caused by complex accounting matters from a reverse takeover and additional audit requirements. The company, which specializes in cannabinoid-based pharmaceuticals for pain management, believes these issues have been resolved for future reporting periods. Investors are alerted to the forward-looking nature of these statements.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
